We also identify local IL-4 produced by intratumor myeloid cells as a critical factor inducing TAP2 downregulation in cancer cells and mediating reduced sensitivity to PD-1 axis blockers (Supplementary Fig. S14). The gene discussed is TAP2; the disease is cancer.